Know Labs Expands Advisory Board

Former American Diabetes Association Chairman, Larry Ellingson, Joins Board

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (OTCQB: KNWN) – a creator and provider of diagnostic solutions, announced today that Larry K. Ellingson has joined its Medical, Scientific and Regulatory Advisory Board.

This press release features multimedia. View the full release here:

Larry K. Ellingson (Photo: Business Wire)

Larry K. Ellingson (Photo: Business Wire)

The Advisory Board was formed to provide counsel and guidance to the Company and its senior management as they work toward FDA approval of their non-invasive UBAND Continuous Glucose Monitor. The Advisory Board is chaired by Know Labs Chief Medical Officer, James (Andy) Anderson, M.D.

The initial members of the Advisory Board in addition to Mr. Ellingson and Dr. Anderson include G. Alexander (Zan) Fleming, M.D. and David C. Klonoff, M.D. (see previous press release).

In adding Mr. Ellingson to the Know Labs Advisory Board, Dr. Anderson remarked, “I have known and worked productively with Larry for most of our careers. He is a committed advocate for all people affected by diabetes and prediabetes. I am extremely pleased to have Larry join our Know Labs team.”

On joining the Know Labs Advisory Board, Mr. Ellingson said, “I was very impressed and excited by the Know Labs technology. People with diabetes and prediabetes desperately need a comfortable, effective, and efficient way to manage their diabetes and improve their lifestyle, and Know Labs presents the first real opportunity of achieving this. I am eager to begin working with Know Labs and assist with bringing this technology to market.”

Mr. Ellingson brings more than four decades of experience in pharmaceutical drug and medical device development, patient-oriented organizational relationships, and successful strategic marketing with a strong emphasis on diabetes and related diseases. His deep knowledge and industry experience will greatly assist Know Labs as it seeks FDA approval of its non-invasive wearable UBAND Continuous Glucose Monitor.

Currently, Mr. Ellingson serves as Principal of Global Diabetes Consulting, where he has worked since 2001. He is co-founder and Vice President of the National Diabetes Volunteer Leadership Council (NDVLC) which advocates for people affected by diabetes focusing on safety, quality of care and access to care.

Mr. Ellingson began his career at Eli Lilly and Company in 1971, serving as Executive Director of Diabetes Care until his retirement in 2001. While at Lilly, Mr. Ellingson was a team leader for ACTOS and leader of the Insulins Product team. He also served as Director of Pharmaceutical New Product Planning for gastrointestinal, skeletal, endocrine and infectious diseases, where he was responsible for global planning and marketed products.

From 2002 to 2005, Mr. Ellingson was a member of the Executive Committee and Chairman of the Board of the American Diabetes Association. From 2010 to 2012, he served on the Executive Committee of the International Diabetes Federation BRIDGES Project.

In addition to Know Labs, Mr. Ellingson is active with committee work and board positions for a number of organizations, including American Diabetes Association, Boston Therapeutics, European Association for the Study of Diabetes, International Diabetes Federation, and Academy of Nutrition and Dietetics.

Mr. Ellingson’s professional career also includes serving as President of Protemix Corporation, a biopharmaceutical product company that specializes in the treatment of diabetes and its cardiovascular complications; CEO and President of Islet Sciences, Inc., a developer of new medicines and technologies for the treatment of metabolic diseases; and Director of Epic Research & Diagnostics, Inc., a biomedical research and device company.

Mr. Ellingson earned an executive MBA from Babson College and received a Bachelor of Science in Pharmacy from North Dakota State University, where he serves as a Trustee and Advisor to the Pharmacy School.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The company’s technology directs structured light or radio waves through a substance or material to capture a unique molecular signature. The Company refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio-RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye. ChromaID and Bio-RFID scanner modules can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests. For more information on Know Labs, visit the company’s website at

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2018, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Know Labs, Inc.
Jordyn Theisen
Ph. 319-321-8470

Source: Know Labs, Inc.